Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells.
The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer.
Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
October 29, 2014
Transgene Announces Events Calendar for Fourth Quarter 2014
October 21, 2014
Transgene Announces Third Quarter 2014 Financial Results
October 9, 2014
TRANSGENE ANNOUNCES MANAGEMENT CHANGES